Skip to main
SNTI
SNTI logo

SNTI Stock Forecast & Price Target

SNTI Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Senti Biosciences Inc. showcases a promising outlook due to the encouraging initial results from its SENTI-202 product candidate, which compares favorably to existing therapies that have less than a 33% complete response rate. Furthermore, the company's investment in establishing in-house GMP manufacturing capabilities suggests enhanced operational efficiency and potential cost reductions, which could positively affect future financial performance. Overall, there is a belief that if upcoming results in 4Q25 continue to outperform benchmarks in terms of patient response and treatment durability, significant upside potential may be realized for Senti Biosciences.

Bears say

Senti Biosciences faces potential downward revisions in its price target due to concerning risk-adjusted projections related to its development pathways. The repeated emphasis on possible negative adjustments to financial estimates indicates a lack of confidence in the company’s ability to achieve its projected milestones. Therefore, the current financial outlook reflects significant uncertainty surrounding Senti Biosciences' future performance in the competitive biotechnology landscape.

SNTI has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Senti Biosciences Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Senti Biosciences Inc (SNTI) Forecast

Analysts have given SNTI a Strong Buy based on their latest research and market trends.

According to 2 analysts, SNTI has a Strong Buy consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $13.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $13.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Senti Biosciences Inc (SNTI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.